G1 Therapeutics, Inc.
G1 Therapeutics, Inc. (GTHX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
gthx · pe ratio · data through Dec 31, 2023
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for G1 Therapeutics, Inc. (GTHX) measures how much investors pay for each dollar of the company's trailing earnings. GTHX's current PE ratio of N/A is calculated by dividing its stock price of $7.16 by its TTM earnings per share of -$0.93.
Source: FMP · /ratios-ttm · /analyst-estimates · 2023-12-31
PE Ratio History
2014 – 2023 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
G1 Therapeutics, Inc.You GTHX | $378M | N/A | — | -$0.93 |
 Checkpoint Therapeutics, Inc. CKPT | $368M | N/A | — | -$1.42 |
 Climb Bio, Inc. CLYM | $734M | N/A | — | -$0.88 |
 Claritev Corporation CTEV | $461M | N/A | — | -$17.30 |
 iTeos Therapeutics, Inc. ITOS | $449M | N/A | — | -$3.32 |
 Orchard Therapeutics plc ORTX | $380M | N/A | — | -$0.62 |
 Revance Therapeutics, Inc. RVNC | $381M | N/A | — | -$3.83 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2023-12-31Latest FY2023 | — | $-0.93 | — | |
2022-12-31 FY2022 | — | $-3.38 | — | |
2021-12-31 FY2021 | — | $-3.54 | — | |
2020-12-31 FY2020 | — | $-2.62 | — | |
2019-12-31 FY2019 | — | $-3.26 | — | |
2018-12-31 FY2018 | — | $-2.56 | — | |
2017-12-31 FY2017 | — | $-2.08 | — | |
2016-12-31 FY2016 | — | $-1.48 | — | |
2015-12-31 FY2015 | — | $-0.99 | — | |
2014-12-31 FY2014 | — | $-0.35 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for G1 Therapeutics, Inc. (GTHX) measures how much investors pay for each dollar of the company's trailing earnings. GTHX's current PE ratio of N/A is calculated by dividing its stock price of $7.16 by its TTM earnings per share of -$0.93.
Frequently asked questions
GTHX pe ratio · 6 questionsGTHX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $7.16 and TTM EPS of -$0.93. Data sourced from Financial Modeling Prep via GTHX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · G1 Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09